Screening to find cancer early, when it’s most treatable
For asymptomatic adults at average risk of cancer, our blood test aims to ensure that all individuals eligible for cancer screening are screened. We believe that by offering an accurate, simple blood test, we can transform cancer screening and help increase compliance rates. We are starting with colorectal cancer, where screening rates can be improved, and will continue to expand to other cancer types.
Cancer screening is a proven way to detect cancer early, when it’s most treatable.23 Unfortunately, many people today aren’t being screened in line with medical guideline recommendations due to barriers of current screening methods which include accessibility and performance.
To help overcome these barriers, we are developing blood-based screening tests, which seek to increase screening rates by offering a simple blood draw that can screen for cancer at its earliest stage. This test has demonstrated to be accurate at detecting colorectal cancer by identifying circulating tumor DNA (ctDNA) in the blood.20
Our ECLIPSE clinical trial is currently underway to further validate the performance of Shield to detect early-stage colorectal cancer, and if successful, the study findings will support submission to the FDA.
Disclaimer: Shield is now available for healthcare professionals to order for eligible individuals in select regions in the U.S. The test [Shield] is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods. Patients with an abnormal blood-based screening result should be referred for a diagnostic colonoscopic evaluation.